Our results showed that miR-106a inhibition reduced IL-1β, IL-6, IL-8 and TGF-β production, indicating that miR-106a may contribute to tumor cell drug resistance by promoting the production of these cytokines (Fig 6). This evidence concerns the gene CXCL8 and neoplasm.